We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · April 28, 2020

Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas

International Journal of Radiation Oncology*Biology*Physics


Additional Info

International Journal of Radiation Oncology*Biology*Physics
Phase II Study of a Temozolomide-Based Chemo-Radiotherapy Regimen for High Risk Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group (RTOG) 0424
Int. J. Radiat. Oncol. Biol. Phys 2020 Apr 03;[EPub Ahead of Print], BJ Fisher, SL Pugh, DR Macdonald, A Chakravatri, GJ Lesser, S Fox, CL Rogers, M Werner-Wasik, T Doyle, JP Bahary, JB Fiveash, JA Bovi, SP Howard, HH Michael Yu, D D'Souza, NN Laack, IJ Barani, Y Kwok, DR Wahl, JF Strasser, M Won, MP Mehta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading